<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490216</url>
  </required_header>
  <id_info>
    <org_study_id>3002-11961-00006857</org_study_id>
    <nct_id>NCT01490216</nct_id>
  </id_info>
  <brief_title>Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence</brief_title>
  <official_title>Open-Label Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate ideal dose or lisdexamfetamine and tolerability,&#xD;
      plus reduction in cocaine use and craving.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate ideal dose or lisdexamfetamine and tolerability, plus reduction in cocaine use and&#xD;
      craving as determined by self-report and cocaine-positive urine samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment&#xD;
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum total lisdexamfetamine dose achieved during the study period defined as the highest amount of medication per day maintained for a seven day period</measure>
    <time_frame>Study weeks 3-6</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>lisdexamfetamine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lisdexamfetamine</intervention_name>
    <description>20mg q.d. to 70mg b.i.d</description>
    <arm_group_label>lisdexamfetamine</arm_group_label>
    <other_name>vyvanse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        .Inclusion Criteria:&#xD;
&#xD;
          1. Men and women between the ages of 18-65 who meet Diagnostic and Statistical Manual -IV&#xD;
             criteria for current cocaine dependence&#xD;
&#xD;
          2. Used cocaine at least four days in the past month&#xD;
&#xD;
          3. Individuals must be in good general health&#xD;
&#xD;
          4. Individuals must be capable of giving informed consent and capable of complying with&#xD;
             study procedures&#xD;
&#xD;
          5. Women of child-bearing age must agree to use a method of contraception with proven&#xD;
             efficacy, consisting of one of the following: 1) Any form of hormonal contraception;&#xD;
             2) Intra-uterine device; 3) Sterilization; 4) Double-barrier contraception which is a&#xD;
             combination of two of the following: condoms, spermicide, diaphragm. Pregnancy tests&#xD;
             will be performed monthly and if a woman becomes pregnant, the study medication will&#xD;
             be discontinued.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals who meet DSM-IV-TR criteria for bipolar disorder, schizophrenia, or any&#xD;
             psychotic disorder other than transient psychosis due to drug abuse&#xD;
&#xD;
          2. Individuals with any other current Axis I psychiatric disorder as defined by DSM-IV-TR&#xD;
             that in the investigator's judgment are unstable, or would be disrupted by study&#xD;
             medication, or are likely to require pharmacotherapy during the study period&#xD;
&#xD;
          3. Individuals physiologically dependent on any other drugs (excluding nicotine or&#xD;
             cannabis) which require medical intervention&#xD;
&#xD;
          4. Individuals with current psychostimulant abuse or dependence (other than cocaine&#xD;
             dependence)&#xD;
&#xD;
          5. Individuals with current suicidal risk&#xD;
&#xD;
          6. Individuals with coronary vascular disease as indicated by history or suspected by&#xD;
             abnormal ECG or history of cardiac symptoms&#xD;
&#xD;
          7. Unstable physical disorders which might make participation hazardous such as&#xD;
             uncontrolled hypertension (SBP &gt; 140, diastolic blood pressure &gt; 90, or heart rate &gt;&#xD;
             100 when sitting quietly), acute hepatitis (patients with chronic mildly elevated&#xD;
             transaminases (&lt; 3x upper limit of normal are acceptable), or uncontrolled diabetes&#xD;
&#xD;
          8. Individuals with a history of seizures, hyperthyroidism and/or glaucoma&#xD;
&#xD;
          9. History of allergic reaction to study medication&#xD;
&#xD;
         10. Women who are pregnant or nursing&#xD;
&#xD;
         11. Currently being prescribed psychotropic medication by another physician (other than&#xD;
             sleep medication)&#xD;
&#xD;
         12. Individuals who are legally mandated (e.g., to avoid incarceration) to participate in&#xD;
             substance abuse treatment program&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc E Mooney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>lisdexamfetamine</keyword>
  <keyword>vyvanse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

